title: Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.
abstract: BACKGROUND
  Radiologically isolated syndrome (RIS) is a sub clinical demyelinating neurological disorder and to date no biomarker that triggers the seminal event has been identified. As for multiple sclerosis (MS), disease activity and clinical course are unpredictable. In MS, exploratory studies reported increased IL-17 levels in CSF but results in detecting IL-17 in serum at different stage of the disease are controversial.
  
  
  OBJECTIVE
  We investigate levels of IL-17 in serum and CSF in patients diagnosed at different stages of demyelinating diseases (RIS, CIS, relapsing remitting (RR) or active multiple sclerosis patients:AMS) as a marker of inflammatory condition.
  
  
  METHODS
  1417 sera has been tested for IL-17A (1177 from active MS, 80 RRMS, 35 RIS, 35 CIS, 10 IIH: idiopathic intracranial hypertension, and 80 controls) and 240 CSF from RIS, CIS, IIH and controls.
  
  
  RESULTS
  No difference has been found between RIS who early clinically converted and CIS patients who rapidly evolve in McDonald or clinically definite MS, nor active MS. No correlation was found with usual MRI or CSF criteria.
  
  
  CONCLUSIONS
  Our results do not confirm that IL-17 can be considerate as a reliable marker of inflammation in the demyelinating spectrum disorders, either in blood or CSF.
authors.affiliation: Neurology, Hopital Pasteur2, Nice, France. Electronic address: Lebrun.c@chu-nice.fr.
authors.forename: Christine
authors.initials: C
authors.lastname: Lebrun
authors.affiliation: Neurology, Hopital Pasteur2, Nice, France.
authors.forename: Mikael
authors.initials: M
authors.lastname: Cohen
authors.affiliation: Neurology, Hopital Purpan, Toulouse, France.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Pignolet
authors.affiliation: Immunology, Hopital Archet, Nice, France.
authors.forename: Barbara
authors.initials: B
authors.lastname: Seitz-Polski
authors.affiliation: Neurology, Hopital Purpan, Toulouse, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Bucciarelli
authors.affiliation: Immunology, Hopital Archet, Nice, France.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Benzaken
authors.affiliation: Mayo Clinic, Rochester, USA.
authors.forename: Orhun
authors.initials: O
authors.lastname: Kantarci
authors.affiliation: Istanbul, Turkey.
authors.forename: Aksel
authors.initials: A
authors.lastname: Siva
authors.affiliation: UTS, Dallas, USA.
authors.forename: Darin
authors.initials: D
authors.lastname: Okuda
authors.affiliation: USC, Los Angeles, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Pelletier
authors.affiliation: Neurology, Hopital Purpan, Toulouse, France.
authors.forename: David
authors.initials: D
authors.lastname: Brassat
mesh_terms: D000328:Adult; D003711:Demyelinating Diseases / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000145:classification; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000097:blood* / Q000134:cerebrospinal fluid*; D008297:Male; D011446:Prospective Studies
chemical_list: D020381:Interleukin-17
keywords: Biomarkers; Clinically isolated syndrome; Interleukin; Multiple sclerosis; Radiologically isolated syndrome